Power Law company profile

PTC Therapeutics

Biotech & Life Sciences · South Plainfield, United States · Founded 1998 · IPO 2013 Unicorn

A science-led, patient-centered biopharmaceutical company focused on discovering, developing and commercializing medicine for patients with rare disease

Valuation

$6.16B

Market cap · May/2026

Revenue

$823M

Latest reported FY

EBITDA

$198M

Latest reported FY

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026 $10B+ revenueThoroughbred · Power Law outcome

Investors

20 investors on PTC Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 20 investors entered at this stage

New Medical Technologies

Brookside Capital

The Column Group

Jennison Associates

Celgene

HBM Healthcare Investments

Manulife Financial

CDI Bioscience

Bay City Capital

HBM BioVentures

Amgen Ventures

Credit Suisse

Adage Capital

Novo Holdings

CDIB Capital Group

Credit Suisse First Boston

Longwood Fund

Cercano Management

HealthCap

Delphi Ventures

PTC Therapeutics mafia

Startups founded by PTC Therapeutics alumni

Former PTC Therapeutics employees who went on to start their own companies. Sorted by Dealroom signal score.

DispelEst. 2014

ESEthan SchmertzlerUnited States

Signal score85

FibronosticsEst. 2015

Roni AmielUnited States

Signal score74

Nionyx BioEst. 2025

MTMagdalena TyrpienUnited States

Signal score71

PikralidaEst. 2019

Stanisław PikulPoland

Signal score71

ZoomiEst. 2012

WJWilliam JuUnited States

Signal score67

InozymeEst. 2016

Axel BolteUnited States

Signal score61

Signify BioEst. 2024

RIRa Session IiUnited States

Signal score56

Book a demo to explore the full alumni network →

Global footprint

Where PTC Therapeutics has talent and traffic

AI talent share

0.3% of workforce is AI talent
(3 of 1,152 staff)

Core AI20.17%

Other AI10.09%

Non-AI workforce1,14999.74%

Workforce by country

31 countries with
team presence

🇺🇸 United States69.9%

🇧🇷 Brazil7.6%

🇮🇪 Ireland4.9%

🇨🇭 Switzerland2.6%

🇬🇧 United Kingdom1.7%

Top 5 of 31 shown

Web traffic by country

41K monthly visits
across markets

🇺🇸 United States58.8%

🏳️ Korea6.6%

🏳️ Republic of6.6%

🇮🇳 India6.3%

🇬🇧 United Kingdom5.1%

Top 5 markets shown

Patent intelligence

$184M patent portfolio · 129 active families

Estimated portfolio value

$184M

3.0% of market cap · comparable to top peer Amicus Therapeutics ($164M)

129 active patent families

Where PTC Therapeutics innovates PharmacologyMedicinal chemistryMolecular biologySepiapterinPterin

Where PTC Therapeutics concentrates vs peers

Each axis is a top-10 topic across PTC Therapeutics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about PTC Therapeutics

An AI-synthesized read of the highest-engagement posts about PTC Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See PTC Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles